Motion sickness patches recalled for being marketed without approved application
ibspot is recalling three boxes of Taoscare Motion Sickness Patches because the product was marketed without an approved new drug application.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: Scored 2 because the record cites the absence of an approved application rather than any identified defect or reported harm.
Plain-English summary
Taoscare Motion Sickness Patches, 36-count box, from Henan Xinyongtal Medical Technology Ltd, are being recalled because the product was marketed without an approved NDA or ANDA.
The recall covers three boxes, distributed in Wyoming and Virginia. No product codes are listed in the record. The FDA has classified the recall as Class II.
The enforcement record describes a marketing authorisation problem rather than any identified defect in the patches, and reports no injuries.
Anyone holding the product should stop using it and follow the seller's instructions.
The recalled product
- Product
- Taoscare Motion Sickness Patches 36-count box, Henan Xinyongtal Medical Technology., Ltd., Address: he nan sheng zhou kou shi huai yang xian gong ye yuan qu, X003SR097N
- Manufacturer
- ibspot
- Category
- Drug — Motion sickness
- Hazard
- unapproved-drug
- regulatory-noncompliance
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- none
Distribution
Distributed in 2 states:
- VA
- WY
Related recalls
Same category
- SevereCleviprex Injectable Emulsion Recall Due to Sterility Assurance Concerns
FDA (Drugs) · 2026-07-22
- ModerateQuality Choice Earwax Removal Kit Carbamide Peroxide Subpotent Drug Recall
FDA (Drugs) · 2026-07-22
- ModerateFamily Wellness Carbamide Peroxide Earwax Removal Kit Subpotent Drug
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22